Reporting of systematic review papers and systematic review authors of different subtypes of individual financial COI, stratified by Cochrane (N=100), non-Cochrane (N=94) and overall (N=194)
| Percentages of papers with at least one author reporting the type of COI; N (%) | Distributions of the percentages of authors per paper reporting COI*; median (IQR) | |||||
|---|---|---|---|---|---|---|
| Overall | Cochrane | Non-Cochrane | Overall | Cochrane | Non-Cochrane | |
| Subtypes of individual financial COI | 60 (31%) | 32 (32%) | 28 (30%) | 35 (20–59) | 29 (20–50) | 42 (27–62) |
| Grant from source(s) same as funding source(s) | 12 (6%) | 7 (7%) | 5 (5%) | 35 (21–54) | 25 (20–50) | 50 (35–61) |
| Grant from source(s) different from funding source(s) | 26 (13%) | 10 (10%) | 16 (17%) | 26 (13–39) | 25 (19–81) | 16 (10–36) |
| Employment | 8 (4%) | 6 (6%) | 2 (2%) | 37 (25–50) | 42 (25–56) | NA |
| Personal fees (other than employment) | 34 (18%) | 14 (14%) | 20 (21%) | 32 (17–50) | 23 (17–38) | 35 (21–54) |
| Non-monetary support | 12 (6%) | 4 (4%) | 8 (9%) | 5 (7–24) | 23 (18–25) | 9 (6–16) |
| Drug/equipment supplies | 3 (2%) | 3 (3%) | 0 (0%) | NA | NA | NA |
| Patent(s) | 1 (1%) | 0 (0%) | 1 (1%) | NA | NA | NA |
| Stocks, bonds, stock options, other securities (eg, equity) | 2 (1%) | 0 (0%) | 2 (2%) | NA | NA | NA |
| ‘Other subtypes’ | 1 (1%) | 0 (0%) | 1 (1%) | NA | NA | NA |
When not applicable, this is due to small numbers or due to cells with a value of zero.
*Calculated for systematic review papers with at least one author reporting the type of individual financial COI (ie, papers counted in the preceding column).
COI, conflict of interest; NA, not applicable.